What Happened?
Shares of personal wellness company WeightWatchers (NASDAQ: WW) jumped 14.3% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved an oral version of the popular weight-loss drug Wegovy.
This development was viewed as a major positive for WeightWatchers, which recently launched its own program that integrated GLP-1 medications. The approval of an oral version of Wegovy, made by Novo Nordisk, made this class of treatment more accessible to consumers. The timing of the news was also significant, as it arrived just before January, which is WeightWatchers' most important period for acquiring new customers. The approval provided a positive signal for the company's strategy of combining its services with medical weight-loss treatments.
Is now the time to buy WeightWatchers? Access our full analysis report here.
What Is The Market Telling Us
WeightWatchers’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. But moves this big are rare even for WeightWatchers and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 19 days ago when the stock dropped 3.4% on the news that investors reacted to weak analyst sentiment and a recent earnings report that showed a significant miss on profits. The company reported a loss per share of $0.44, which was wider than the consensus estimate of a $0.14 loss. This indicated that the company's financial performance was worse than experts had predicted. Although the company's revenue of $172.09 million slightly beat expectations, the larger-than-expected loss seemed to be the primary concern driving the stock down. The overall analyst view was cautious, with an average rating of "Reduce" based on two "Hold" ratings and one "Sell" rating.
WeightWatchers is up 12.2% since the beginning of the year, but at $30.30 per share, it is still trading 32.5% below its 52-week high of $44.89 from August 2025. Investors who bought $1,000 worth of WeightWatchers’s shares at the IPO in June 2025 would now be looking at an investment worth $1,122.
Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report.
